Hugh E. Stephenson Professor of Surgery (Surgical Oncology), School of Medicine
NextGen Focus Area: Cancer and Immunology
Kevin Staveley-O’Carroll has a broad background in all phases of therapy development and implementation, including experience leading multidisciplinary cancer-care teams, leading large National Cancer Institute and U.S. Veterans Affairs grants with multiple investigators and leading investigator-initiated clinical trials. His clinical expertise is focused on liver, pancreas and foregut tumors, and his research and therapy-development activities center around enhancing the immune response to these tumors.
Precision Health Impact:
- Developing new cancer treatments.
- Investigating immunotherapeutic, chemotherapeutic and nanoparticle agents in a variety of cancers.
Publications:
- Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, et al. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. 2018 Mar;154(4):1024-1036.e9.
- Li G, Liu D, Cooper TK, Kimchi ET, Qi X, Avella DM, et al. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol. 2017 Jan;66(1):75–85.
- Yang M, Qi X, Li N, Kaifi JT, Chen S, Wheeler AA, et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun. 2023 Jan 16;14(1):228.
PubMed
Email: ocarrollk@health.missouri.edu
Department website: https://www.muhealth.org/doctors/kevin-staveley-ocarroll-md